top of page

Mwandishi:

Mhariri:

Imeboershwa:

ULY CLINIC

ULY CLINIC

17 Februari 2026, 14:31:27

Contact Dermatitis
Contact Dermatitis

Contact Dermatitis

Contact dermatitis is a delayed hypersensitivity reaction of the skin occurring after direct contact with a chemical or allergen.

  • Common triggers include:

    • Dyes

    • Perfumes

    • Rubber

    • Nickel

    • Certain drugs

    • Skin preparations containing lanolin, iodine, antihistamines, or neomycin

  • The reaction may be acute or chronic, with varying severity depending on the concentration of the allergen and duration of exposure.

  • Pathophysiology involves type IV hypersensitivity, mediated by T-lymphocytes, leading to inflammation, edema, and vesicle formation.


Signs & Symptoms

  • Acute phase:

    • Red, papulo-vesicular rash with ill-defined margins

    • Itching, which may be severe

    • Blisters and weeping lesions, sometimes crusted

  • Chronic phase (repeated exposure or delayed treatment):

    • Dry, cracked, scaly skin

    • Lichenification (thickened skin)

    • Swelling, burning, or tenderness

  • Distribution: Confined to areas of contact with the offending agent, often linear or patterned according to exposure.


Diagnostic Criteria

Diagnosis is clinical, based on history and lesion appearance:

  • Red papulo-vesicular rash with ill-defined margins

  • Severe pruritus

  • Dry, cracked, or scaly skin in chronic cases

  • Blisters, draining fluid, or crusting in severe dermatitis

  • Swelling, burning, or tenderness at affected sites

Note: Consider patch testing in recurrent or unclear cases to identify the responsible allergen.


Investigation

  • Patch testing: Gold standard to identify allergens causing delayed-type hypersensitivity

  • Skin biopsy: Rarely required; may help distinguish from other eczematous dermatoses

  • Cultures: Only if secondary infection is suspected


Treatment

Management involves eliminating the trigger, supportive care, and pharmacologic therapy.


Non-Pharmacological Treatment

  • Avoidance of allergen: Essential to prevent recurrence

  • Protective clothing or gloves if exposure is unavoidable

  • Gentle skin care:

    • Use mild soaps or emollients

    • Avoid scrubbing or harsh cleansers


Pharmacological Treatment

  • Topical corticosteroids (first-line therapy):

    • Betamethasone valerate 0.025% cream/ointment applied 12-hourly for two weeks

    • Super-potent or potent steroids may be needed for severe lesions

Notes on topical therapy:

  • A single application at night under occlusion is often more effective than multiple daytime applications

  • Avoid long-term continuous use to prevent skin atrophy, striae, or pigmentation changes

  • Adjunctive therapy:

    • Wet dressings for acute weeping lesions

    • Oral antihistamines for severe pruritus (e.g., cetirizine or loratadine)

  • Secondary infection management:

    • If bacterial infection develops (yellow crusting or pus), consider topical or systemic antibiotics as indicated


Prevention

  • Identify and avoid known allergens

  • Educate patients on safe handling of chemicals

  • Use protective gloves and barrier creams when contact is unavoidable

  • Early treatment of minor reactions to prevent chronic dermatitis and lichenification


Complications

  • Chronic lichenified skin

  • Persistent hyperpigmentation or hypopigmentation

  • Secondary bacterial infection

  • Reduced quality of life due to pruritus and cosmetic disfigurement


Prognosis

  • Acute contact dermatitis usually resolves within 2–3 weeks with proper treatment

  • Chronic exposure may lead to relapsing or persistent lesions

References

  1. Tanzania Ministry of Health. Standard Treatment Guidelines & National Essential Medicines List (STG/NEMLIT). 7th ed. Dodoma: MoH; 2023.

  2. Fonacier L, et al. Contact Dermatitis. J Allergy Clin Immunol Pract. 2015;3(1):1–12.

  3. Rietschel RL, Fowler JF. Fisher’s Contact Dermatitis. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2019.

  4. Warshaw EM, et al. Patch Testing in Contact Dermatitis. Dermatitis. 2014;25(3):119–135.

  5. World Health Organization. WHO Model Formulary 2023. Geneva: WHO; 2023.


Imeandikwa;

3 Novemba 2020, 12:16:31

bottom of page